Iloperidone binding to human and rat dopamine and 5-HT receptors

European Journal of Pharmacology

Volumn 317, Issue 2-3, 1996, Pages 417-423

  Kongsamut, Sathapana ^a   Roehr, Joachim E ^a   Cai, Jidong ^a   Hartman, Harold B ^a   Weissensee, Paul ^a   Kerman, Lisa L ^a   Tang, Lei ^a   Sandrasagra, Anthony ^a  

^a SANOFI   (France)

Author keywords

5 HT receptor; Antipsychotic agent; Dopamine receptor; Psychotic disorder; Schizophrenia

Indexed keywords

BUTACLAMOL; CLOZAPINE; DOPAMINE RECEPTOR; ETICLOPRIDE; HALOPERIDOL; ILOPERIDONE; MIANSERIN; OLANZAPINE; QUETIAPINE; RECEPTOR SUBTYPE; RISPERIDONE; SEROTONIN RECEPTOR; SPIPERONE;

ANIMAL CELL; ARTICLE; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHO CELLS; CRICETINAE; HUMANS; ISOXAZOLES; KINETICS; PIPERIDINES; RATS; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; RECEPTORS, DOPAMINE D5; RECEPTORS, SEROTONIN;

EID: 0030593937     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00840-0     Document Type: Article

References (29)

1. Baldessarini, R.J., 1996, Drugs and the treatment of psychiatric disorders, in: The Pharmacological Basis of Therapeutics, 9th edn., eds. J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon and A.G. Gilman, p. 399.
2. Baldessarini, R.J., D. Hulston-Lyons, A. Campbell, E. Marsh and B.M. Cohen, 1992, Do central antiadrenergic actions contribute to the atypical properties of clozapine?, Br. J. Pharmacol. 160 (Suppl. 17), 12.
3. Beasley, C.M., G. Tollefson, P. Tran, W. Satterlee, T. Sanger, S. Hamilton and the Olanzapine HGAD Study Group, 1996, Olanzapine versus placebo and haloperidol, acute phase results of the North American double-blind olanzapine trial, Neuropsychopharmacology 14, 111.
4. 2 receptor blocking agent, Curr. Ther. Res. 40, 492.
5. Borison, R.L., F.J. Huff, J. Veraklis, L. Griffiths, R. Ramaswamy and J. Shipley, 1995, Efficacy of 2 and 4 mg BID iloperidone (HP 873) administered to schizophrenic patients for 42 days, ACNP Abstr. 34, 135.
6. Bymaster, F.P., D.O. Calligaro, J.F. Falcone, R.D. Marsh, N.A. Moore, N.C. Tye, P. Seeman and D.T. Wong, 1996, Radioreceptor binding profile of the atypical antipsychotic olanzapine, Neuropsychopharmacology 14, 87.
7. 1C sites, Eur. J. Pharmacol. 191, 93.
8. Corbett, R., H.B. Hartman, L.L. Kerman, A.T. Woods, J.T. Strupczewski, G.C. Helsley, P.G. Conway and R.W. Dunn, 1993, Effects of atypical antipsychotic agents on social behavior in rodents, Pharmacol. Biochem. Behav. 45, 9.
9. Creese, I., D.R. Burt and S.H. Snyder, 1978, Biochemical actions of neuroleptic drugs: focus on the dopamine receptor, in: Handbook of Psychopharmacology, eds. L.L. Iversen, S.D. Iversen and S.H. Snyder, Vol. 10, p. 37.
10. Davis, K.L., R.S. Kahn, G. Ko and M. Davidson, 1991, Dopamine in schizophrenia: a review and reconceptualization, Am. J. Psychiatry 148, 1474.
11. Hoyer, D., D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, E.J. Mylecharane, P.R. Saxena and P.P.A. Humphrey, 1994, VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin), Pharmacol. Rev. 46, 157.
12. 2 properties, J. Pharmacol. Exp. Ther. 244, 685.
13. Jarvie, K.R. and M.G. Caron, 1993, Heterogeneity of dopamine receptors, Adv. Neurol. 60, 325.
14. Leadbetter, R., M. Shutty, D. Pavalonis, V. Vieweg, P. Higgins and M. Downs, 1992, Clozapine-induced weight gain: prevalence and clinical relevance, Am. J. Psychiatry 149, 68.
15. Leysen, J.E., W. Gommeren, A. Eens, D. Dechaffoy de Cowicelles, J.C. Stoof and P.A.J. Janssen, 1988, Biochemical profile of risperidone, a new antipsychotic, J. Pharmacol. Exp. Ther. 247, 661.
16. 2 receptors, Psychopharmacology 112, S40.
17. 3H]RP 62203 binding in the rat brain, Eur. J. Pharmacol. 233, 37.
18. Meltzer, H.Y., 1989, Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia, Psychopharmacology 99, S18.
19. Owens, D.G., 1994, Extrapyramidal side effects and tolerability of risperidone: a review, J. Clin. Psychiatry 55 (Suppl.), 29.
20. Rao, M.L. and H.-J. Möller, 1994, Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment, Neuropsychobiology 30, 160.
21. Roth, B.L., S.C. Craigo, M.S. Choudhary, A. Uluer, F.J. Monsma Jr, Y. Shen, H.Y. Meltzer and D.R. Sibley, 1994, Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors, J. Pharmacol. Exp. Ther. 268, 1403.
22. Sainati, S.M., J.W. Hubbard, E. Chi, K. Grasing and M. Brecher, 1995, Safety, tolerability and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic, J. Clin. Pharmacol. 35, 713.
23. Saller, C.F. and A.I. Salama, 1993, Seroquel: biochemical profile of a potential atypical antipsychotic, Psychopharmacology 112, 285.
24. Schwartz, J.-C., B. Giros, M.-P. Martres and P. Sokoloff, 1992, The dopamine receptor family: molecular biology and pharmacology, Semin. Neurosci. 4, 99.
25. 2 receptors, J. Pharmacol. Exp. Ther. 266, 1374.
26. 2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873), J. Med. Chem. 38, 1119.
27. 2 receptor antagonist activity, J. Pharmacol. Exp. Ther. (in press).
28. Szewczak, M.R., R. Corbett, D.K. Rush, C.A. Wilmot, P.G. Conway, J.T. Strupczewski and M.L. Cornfeldt, 1995, The pharmacological profile of iloperidone, a novel atypical antipsychotic agent, J. Pharmacol. Exp. Ther. 274, 1404.
29. 2c serotonin receptors, Nature 374, 542.